Innovative solutions that meet the most stringent quality regulations and are compatible with food industry standards ...

Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to ...

Traditionally, the diagnosis of Alzheimer’s disease has been based on informant interviews and clinical assessments of memory, cognition, behaviour, and mood. To increase diagnostic confidence, ...

A new study from Stanford University sheds light on why some older adults maintain strong memory while others struggle, even when both groups appear equally healthy. Researchers found that differences ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

A novel PET imaging approach has revealed distinct patterns of brain inflammation in patients with progressive apraxia of ...

The first clinical guideline on the use of blood biomarker tests could help clinicians choose the most appropriate test to ...

Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer's Disease ...

No new safety findings were observed in the OLE with continued lecanemab treatment over four years. Rates of amyloid-related imaging abnormalities (ARIA) decreased after the initial 12 months and ...

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...